Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders Research & Development Business Strategies

Amgen’s Plan To Go Big In Obesity

  • News

Executive Summary

Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

Wegovy Starting Doses Restrictions Will Continue Through The Year

Supply of the obesity drug has outpaced demand in the US, and Novo Nordisk said that will persist throughout 2023.

SELECT: Novo Nordisk Comes Roaring Back

After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Metabolic Disorders Research & Development Business Strategies
Latest Headlines

Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer

What Verona Needs To Make COPD Drug Ensifentrine A Success

Biopharma’s Must-Know Q4 Catalysts

Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness

See All
UsernamePublicRestriction

Register

SC149034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By